IMPACT OF THE OPERATION CIGLITAZONE ON PPAR ACTIVATION AND APOPTOSIS PROCESS IN MODELS OF GASTROINTESTINAL CANCER IN VITRO

Aldona Olechowska-Jarząb, A. Targosz, A. Ptak-Belowska
{"title":"IMPACT OF THE OPERATION CIGLITAZONE ON PPAR ACTIVATION AND APOPTOSIS PROCESS IN MODELS OF GASTROINTESTINAL CANCER IN VITRO","authors":"Aldona Olechowska-Jarząb, A. Targosz, A. Ptak-Belowska","doi":"10.53555/eijbps.v4i1.28","DOIUrl":null,"url":null,"abstract":"Background: Peroxisome proliferator-activated receptors (PPAR-γ) are nuclear transcription factors which affect the stimulation of glucose and lipid metabolism, modulation of inflammation, tissue sensitivity to insulin, immune response, cell proliferation and differentiation. Current research on PPAR-γ receptors is contradictory.  \nA significant part of the research suggests that these receptors may be targeted for anti-cancer therapy and have anti-inflammatory properties. Other analyzes speculate on the role of PPAR-γ in promoting cancer. It is therefore important that further studies help to better understand the role of PPAR-γ receptors, which may be relevant in the context of public health and cancer therapy \nMethods: The purpose of the study was to determine the effect of ciglitazone (10 μM) on expression of PPAR-γ receptors. In addition, it was investigated whether action on PPAR-γ nuclear receptors with a specific ligand concentration (10 μM of ciglitazone) could lead to increased expression of apoptotic protein (Bcl-2, PKB/Akt) in gastric cancer cells (PANC-1, HT-29) in models In vitro. The effects of ciglitazone were tested in HT-29 and PANC-1 cell lines by MTT growth test (tetrazolium growth assay) for 48 hours post-treatment. Investigation of the relationship between ciglitazone and PPARγ in the context of apoptosis was investigated at the protein level by Western Blot analysis.  \nResults: The results obtained reflect the trend in the publication. In the conducted studies, it was observed that at 10 and 20 μM concentration of ciglitazone affects the growth of the investigated cell lines (PANC-1, HT-29). In addition, studies have shown that this drug increases the activity of PPAR-γ receptors and may affect the kinase gene Akt and Bcl-2 through the receptors themselves. \nConclusion: The studies show that treatment of cancer cells 10 μM ciglitazone for a certain time affects the upregulation of anti-apoptotic proteins. What may suggest that certain types of ligand does not result in inhibition of the process of carcinogenesis? Therefore, studies on the effect of PPAR-γ receptors and their ligands on intestinal tumors should be conducted.","PeriodicalId":257195,"journal":{"name":"EPH - International Journal of Biological & Pharmaceutical Science","volume":"20 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2019-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EPH - International Journal of Biological & Pharmaceutical Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.53555/eijbps.v4i1.28","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Peroxisome proliferator-activated receptors (PPAR-γ) are nuclear transcription factors which affect the stimulation of glucose and lipid metabolism, modulation of inflammation, tissue sensitivity to insulin, immune response, cell proliferation and differentiation. Current research on PPAR-γ receptors is contradictory.  A significant part of the research suggests that these receptors may be targeted for anti-cancer therapy and have anti-inflammatory properties. Other analyzes speculate on the role of PPAR-γ in promoting cancer. It is therefore important that further studies help to better understand the role of PPAR-γ receptors, which may be relevant in the context of public health and cancer therapy Methods: The purpose of the study was to determine the effect of ciglitazone (10 μM) on expression of PPAR-γ receptors. In addition, it was investigated whether action on PPAR-γ nuclear receptors with a specific ligand concentration (10 μM of ciglitazone) could lead to increased expression of apoptotic protein (Bcl-2, PKB/Akt) in gastric cancer cells (PANC-1, HT-29) in models In vitro. The effects of ciglitazone were tested in HT-29 and PANC-1 cell lines by MTT growth test (tetrazolium growth assay) for 48 hours post-treatment. Investigation of the relationship between ciglitazone and PPARγ in the context of apoptosis was investigated at the protein level by Western Blot analysis.  Results: The results obtained reflect the trend in the publication. In the conducted studies, it was observed that at 10 and 20 μM concentration of ciglitazone affects the growth of the investigated cell lines (PANC-1, HT-29). In addition, studies have shown that this drug increases the activity of PPAR-γ receptors and may affect the kinase gene Akt and Bcl-2 through the receptors themselves. Conclusion: The studies show that treatment of cancer cells 10 μM ciglitazone for a certain time affects the upregulation of anti-apoptotic proteins. What may suggest that certain types of ligand does not result in inhibition of the process of carcinogenesis? Therefore, studies on the effect of PPAR-γ receptors and their ligands on intestinal tumors should be conducted.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
手术西格列酮对体外胃肠道肿瘤模型ppar活化和凋亡过程的影响
背景:过氧化物酶体增殖物激活受体(PPAR-γ)是影响糖脂代谢刺激、炎症调节、组织对胰岛素的敏感性、免疫反应、细胞增殖和分化的核转录因子。目前关于PPAR-γ受体的研究存在矛盾。研究的一个重要部分表明,这些受体可能是抗癌治疗的目标,并具有抗炎特性。其他分析推测PPAR-γ在促进癌症中的作用。因此,进一步的研究有助于更好地了解PPAR-γ受体的作用,这可能与公共卫生和癌症治疗有关。方法:本研究的目的是确定西格列酮(10 μM)对PPAR-γ受体表达的影响。此外,我们还研究了特定配体浓度(10 μM的西格列酮)作用于PPAR-γ核受体是否会导致体外模型胃癌细胞(PANC-1, HT-29)中凋亡蛋白(Bcl-2, PKB/Akt)的表达增加。用MTT生长试验(四氮唑生长试验)检测西格列酮对HT-29和PANC-1细胞株48小时的影响。Western Blot分析在蛋白水平上研究西格列酮与PPARγ在细胞凋亡中的关系。结果:所得结果反映了本刊趋势。在所进行的研究中,观察到10和20 μM浓度的西格列酮对所研究的细胞系(PANC-1, HT-29)的生长有影响。此外,研究表明,该药可增加PPAR-γ受体的活性,并可能通过受体本身影响激酶基因Akt和Bcl-2。结论:研究表明,10 μM西格列酮作用癌细胞一定时间后可影响抗凋亡蛋白的上调。什么可能表明某些类型的配体不能抑制癌变过程?因此,应进一步研究PPAR-γ受体及其配体对肠道肿瘤的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
STUDY OF VIRUSES MATERIAL RNA OR DNA BIODIVERSITY OF WILD MEDICINAL PLANTS IN SOME AREAS OF THE SOUTHERN SLOPE OF THE HISSAR RIDGE STATUS REPORT OF MYCOBACTERIUM TUBERCULOSIS IN REPUBLIC OF MALAWI, CENTRAL AFRICA (14.32’39.954’S AND 35.11’26.269’E) HYDROGEN PEROXIDE IMPEDES NK CELL AND T CELL MEDIATED CYTOTOXICITY AGAINST COLON CANCER CELL IMPACT OF THE OPERATION CIGLITAZONE ON PPAR ACTIVATION AND APOPTOSIS PROCESS IN MODELS OF GASTROINTESTINAL CANCER IN VITRO
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1